#prostatecancer 검색 결과

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8 #NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

JournalofNucMed's tweet image. ²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8

#NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

Hot Off the Press. shorturl.at/9Dnqe R&D of a new device with 3D Planning and MR Fusion for focal cryoablation using @UroNav @PhilipsHealth. Flattening the learning curve. Built & Tested at @NorthwellHealth #focal2025 #prostatecancer @FocalSociety

DrRastinehad's tweet image. Hot Off the Press. shorturl.at/9Dnqe R&amp;amp;D of a new device with 3D Planning and MR Fusion for focal cryoablation using @UroNav @PhilipsHealth.  Flattening the learning curve.  Built &amp;amp; Tested at @NorthwellHealth #focal2025 #prostatecancer @FocalSociety

Thank you @therapy_focal for the 1st place recognition at #FOCAL2025! With Dr. @TarikBenidir’s mentorship/guidance and @GrantDuVall_’s continued research support, our team will continue driving forward evidence-based care for #prostatecancer. Go Gators 🐊! @UF_Urology

ShayRajavel's tweet image. Thank you @therapy_focal for the 1st place recognition at #FOCAL2025! 

With Dr. @TarikBenidir’s mentorship/guidance and @GrantDuVall_’s continued research support, our team will continue driving forward evidence-based care for #prostatecancer.

Go Gators 🐊! @UF_Urology

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile…

_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…
_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…
_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…

One man dies every 45 minutes from #ProstateCancer - that's half a football match. 👏 That's why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited. 👊 It’s about time we relegated prostate cancer. #BHAFC l @ProstateUnited l @LMA_Managers

ProstateUK's tweet image. One man dies every 45 minutes from #ProstateCancer - that&apos;s half a football match.

👏 That&apos;s why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited.

👊 It’s about time we relegated prostate cancer.

#BHAFC l @ProstateUnited l @LMA_Managers
ProstateUK's tweet image. One man dies every 45 minutes from #ProstateCancer - that&apos;s half a football match.

👏 That&apos;s why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited.

👊 It’s about time we relegated prostate cancer.

#BHAFC l @ProstateUnited l @LMA_Managers

Radiation therapy for #prostatecancer is more precise, convenient, and personalized than ever before. From #SBRT to MRI-guided and adaptive approaches, MSK experts are leading advances that improve outcomes and protect quality of life for patients with #prostatecancer. Learn…

MSKCancerCenter's tweet image. Radiation therapy for #prostatecancer is more precise, convenient, and personalized than ever before. From #SBRT to MRI-guided and adaptive approaches, MSK experts are leading advances that improve outcomes and protect quality of life for patients with #prostatecancer. Learn…

Prostate cancer w/foamy gland features - note the pyknotic nuclei in foamy glands = deceptively benign-appearing Fortunately, as in this example, often admixed with usual acinar #prostatecancer with more amphophilic cytoplasm, prominent nucleoli, etc. #gupath

rovingatuscap's tweet image. Prostate cancer w/foamy gland features - note the pyknotic nuclei in foamy glands = deceptively benign-appearing

Fortunately, as in this example, often admixed with usual acinar #prostatecancer with more amphophilic cytoplasm, prominent nucleoli, etc. #gupath

#ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer @myESMO

dmukherji's tweet image. #ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer @myESMO

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System…

OncoAlert's tweet image. The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 &amp;amp; Dr. Gil Morgan🇺🇸  have selected the OncoAlert TOP🔟  #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System…

📢 In European Urology: The PROBASE trial shows that in men aged 45–50, systematic biopsy detects 94% of significant prostate cancers vs 74% with MRI-targeted biopsy. ➡️ A combined SBx + TBx approach is essential. 🔗 buff.ly/q1QUurO #ProstateCancer #Urology #Screening

EUplatinum's tweet image. 📢 In European Urology: The PROBASE trial shows that in men aged 45–50, systematic biopsy detects 94% of significant prostate cancers vs 74% with MRI-targeted biopsy.
➡️ A combined SBx + TBx approach is essential.
🔗 buff.ly/q1QUurO 
#ProstateCancer #Urology #Screening

CamPROBE:✅Safe✅Simple✅Cost Effective CamPROBE from @medovate is an innovative device designed to perform transperineal prostate biopsies under local anaesthetic – providing a safer and more comfortable experience for patients. #prostate #prostatebiopsies #prostatecancer


New treatments are changing the game for metastatic #ProstateCancer! Learn about the evolution of chemohormonal therapy & what's next in care from expert @PBarataMD @caseccc and @zklaassen_md @GACancerCenter > bit.ly/4dn5Vti #CancerResearch


🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere. #prostatecancer @therapy_focal

CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal
CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal
CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal

Men with PSA <1–2 ng/ml at 60 are very unlikely to die from prostate cancer. Screening them again may just cause harm, not help. #ProstateCancer @JNCI_Now @APCCC_Lugano @PCFnews doi.org/10.1093/jnci/d…

DrYukselUrun's tweet image. Men with PSA &amp;lt;1–2 ng/ml at 60 are very unlikely to die from prostate cancer. Screening them again may just cause harm, not help. 
#ProstateCancer 
@JNCI_Now @APCCC_Lugano @PCFnews 
doi.org/10.1093/jnci/d…

If there’s not enough evidence for #ProstateCancer screening, we’ll be disappointed - but we won’t lose hope. Our TRANSFORM trial will deliver the definitive evidence we need. We’re committed to better diagnosis and treatment until no man’s diagnosis is left to chance.

ProstateUK's tweet image. If there’s not enough evidence for #ProstateCancer screening, we’ll be disappointed - but we won’t lose hope.

Our TRANSFORM trial will deliver the definitive evidence we need.

We’re committed to better diagnosis and treatment until no man’s diagnosis is left to chance.

Dr. @Achard_Verane shares her thoughts on the management of this patient with postoperative #ProstateCancer recurrence. 🧑‍💻 Watch the complete 30-minute webinar here: library.mirrorsmed.org/index.php/manu… & check out the 🧑‍⚕️ Case-based discussion with @BertrandTOMBAL 📰 Review of recent data on…


The PSMA-targeted PET/CT scan is a breakthrough tool that catches cancer that standard imaging techniques may miss, offering a more precise & accurate method of localizing #prostatecancer cells. Prioritize your health by learning more & scheduling yours: tinyurl.com/ysdwybvs

HouMetroUro's tweet image. The PSMA-targeted PET/CT scan is a breakthrough tool that catches cancer that standard imaging techniques may miss, offering a more precise &amp;amp; accurate method of localizing #prostatecancer cells. Prioritize your health by learning more &amp;amp; scheduling yours: tinyurl.com/ysdwybvs

Healthwatch across #GreaterManchester want to better understand and improve support for men living with or affected by #prostatecancer. Have you had or been living with Prostate Cancer? Perhaps you know someone who has. smartsurvey.co.uk/s/HWBPCS/ #healthwatchstockport #stockport

HWStockport's tweet image. Healthwatch across #GreaterManchester want to better understand and improve support for men living with or affected by #prostatecancer. Have you had or been living with Prostate Cancer? Perhaps you know someone who has. 
smartsurvey.co.uk/s/HWBPCS/

#healthwatchstockport #stockport

²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8 #NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

JournalofNucMed's tweet image. ²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8

#NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

Tazemetostat + talazoparib for metastatic castration-resistant #ProstateCancer. @AtishChoudhury @DanaFarber joins Evan Yu, MD @fredhutch to discuss a first-in-human trial combining EZH2 and PARP inhibition in #mCRPC. #WatchNow on UroToday > bit.ly/4oVI9tJ

urotoday's tweet image. Tazemetostat + talazoparib for metastatic castration-resistant #ProstateCancer. @AtishChoudhury @DanaFarber joins Evan Yu, MD @fredhutch to discuss a first-in-human trial combining EZH2 and PARP inhibition in #mCRPC. #WatchNow on UroToday &amp;gt; bit.ly/4oVI9tJ

meet both Captains, who have been leading brilliant fundraising efforts, including a raffle and on-course forfeits! We’re very grateful to everyone at Bramley Golf Club for your generosity and support. #ProstateCancer

_ProstateProjec's tweet image. meet both Captains, who have been leading brilliant fundraising efforts, including a raffle and on-course forfeits! We’re very grateful to everyone at Bramley Golf Club for your generosity and support. #ProstateCancer

The Times: “However, the tests …while also leading to false positives, which can lead to men having unnecessary treatment with side-effects such as incontinence and erectile dysfunction.” Bollocks.No one has treatment just on the back of a PSA test. #ProstateCancer


New #research from Dr. Neal Patel and @WeillCornell @WCMUrology colleagues found that a proportion of men diagnosed with low grade #ProstateCancer have higher-risk disease than suggested by biopsy: bit.ly/3VoF2x2


LOW & INTERMEDIATE RISK #ProstateCancer group meets tonight! Drop into a supportive group of peers who have all been through something similar. We got your back 🙌 2nd & 4th Mondays 8pm EST #prostatecancer ➡️ gotomeet.me/AnswerCancer

ancan501c3's tweet image. LOW &amp;amp; INTERMEDIATE RISK #ProstateCancer group meets tonight! Drop into a supportive group of peers who have all been through something similar. We got your back 🙌
2nd &amp;amp; 4th Mondays 8pm EST
#prostatecancer
➡️ gotomeet.me/AnswerCancer

Studies suggest that ejaculating at least 21 times a month may lower the risk of #prostatecancer #TV #Radio #Medical

musiccritic4U's tweet image. Studies suggest that ejaculating at least 21 times a month may lower the risk of #prostatecancer #TV #Radio #Medical

Let’s raise awareness that can save lives. Black men are twice as likely to be diagnosed with #prostatecancer Michael Lewis from Dudley shares how a PSA test caught his cancer early: 👉🏾 voice-online.co.uk/sponsored-2/20…

NHS_WMCA's tweet image. Let’s raise awareness that can save lives.
Black men are twice as likely to be diagnosed with #prostatecancer 
Michael Lewis from Dudley shares how a PSA test caught his cancer early:
👉🏾 voice-online.co.uk/sponsored-2/20…

Former President Joe Biden (82) begins intensive treatment for stage IV metastatic prostate cancer with radiation & hormone therapy. #JoeBiden #ProstateCancer #CancerAwareness #HealthMatters #EarlyDetection drugtodayonline.com/medical-news/n…

DTMedicalTimes's tweet image. Former President Joe Biden (82) begins intensive treatment for stage IV metastatic prostate cancer with radiation &amp;amp; hormone therapy.

#JoeBiden #ProstateCancer #CancerAwareness #HealthMatters #EarlyDetection

drugtodayonline.com/medical-news/n…

PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis. #prostatecancer #bone pubmed.ncbi.nlm.nih.gov/40450503/


Thank you @JamesFrith for supporting @PCR_News #ProactiveForYourProstate campaign. By championing this campaign you are helping us get one step closer to improving #prostatecancer screening in the UK. I hope you attend PCR’s reception in Parliament on Oct 14.


🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

PRIME trial: Biparametric MRI (no contrast) caught significant prostate cancer as well as full multiparametric scans. Shorter, cheaper, safer, could reset the standard of care worldwide? #ProstateCancer #Oncology doi:10.1001/jama.2025.13722 @JAMA_current @APCCC_Lugano @PCFnews

DrYukselUrun's tweet image. PRIME trial: 
Biparametric MRI (no contrast) caught significant prostate cancer as well as full multiparametric scans.
Shorter, cheaper, safer, could reset the standard of care worldwide?
 #ProstateCancer #Oncology doi:10.1001/jama.2025.13722
@JAMA_current @APCCC_Lugano @PCFnews…

📢 In European Urology: The PROBASE trial shows that in men aged 45–50, systematic biopsy detects 94% of significant prostate cancers vs 74% with MRI-targeted biopsy. ➡️ A combined SBx + TBx approach is essential. 🔗 buff.ly/q1QUurO #ProstateCancer #Urology #Screening

EUplatinum's tweet image. 📢 In European Urology: The PROBASE trial shows that in men aged 45–50, systematic biopsy detects 94% of significant prostate cancers vs 74% with MRI-targeted biopsy.
➡️ A combined SBx + TBx approach is essential.
🔗 buff.ly/q1QUurO 
#ProstateCancer #Urology #Screening

Dami is running the @RoyalParksHalf next Sunday in memory of his grandfather, who passed away from #ProstateCancer three years ago. He will be joined by over 350 runners taking on the stunning route to help fund lifesaving research for men 💙 #GrandparentsDay l #RoyalParksHalf

ProstateUK's tweet image. Dami is running the @RoyalParksHalf next Sunday in memory of his grandfather, who passed away from #ProstateCancer three years ago.

He will be joined by over 350 runners taking on the stunning route to help fund lifesaving research for men 💙

#GrandparentsDay l #RoyalParksHalf
ProstateUK's tweet image. Dami is running the @RoyalParksHalf next Sunday in memory of his grandfather, who passed away from #ProstateCancer three years ago.

He will be joined by over 350 runners taking on the stunning route to help fund lifesaving research for men 💙

#GrandparentsDay l #RoyalParksHalf

²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8 #NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

JournalofNucMed's tweet image. ²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. ow.ly/8WT850X6Xc8

#NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza

Excited to share our new study in 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝! We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target. Huge thanks to @mishabeltran for her mentorship! bit.ly/3HRIvAU @PCF_Science @CDMRP

Bajji's tweet image. Excited to share our new study in 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝!
We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target.
Huge thanks to @mishabeltran for her mentorship!

bit.ly/3HRIvAU

@PCF_Science @CDMRP

Hot Off the Press. shorturl.at/9Dnqe R&D of a new device with 3D Planning and MR Fusion for focal cryoablation using @UroNav @PhilipsHealth. Flattening the learning curve. Built & Tested at @NorthwellHealth #focal2025 #prostatecancer @FocalSociety

DrRastinehad's tweet image. Hot Off the Press. shorturl.at/9Dnqe R&amp;amp;D of a new device with 3D Planning and MR Fusion for focal cryoablation using @UroNav @PhilipsHealth.  Flattening the learning curve.  Built &amp;amp; Tested at @NorthwellHealth #focal2025 #prostatecancer @FocalSociety

PURE-MRI study results How well do physicians contour prostate and urethra on MRI? ✅Prostate, including inexperienced docs ❌Urethra: not good AI 🤖better than 👨🏻‍⚕️ 👏🏻@UCSanDiego MS4 Lily Nguyen #ASTRO25 #ProstateCancer #radonc

TylerSbrt's tweet image. PURE-MRI study results

How well do physicians contour prostate and urethra on MRI?

✅Prostate, including inexperienced docs

❌Urethra: not good

AI 🤖better than 👨🏻‍⚕️ 

👏🏻@UCSanDiego MS4 Lily Nguyen

#ASTRO25 #ProstateCancer #radonc
TylerSbrt's tweet image. PURE-MRI study results

How well do physicians contour prostate and urethra on MRI?

✅Prostate, including inexperienced docs

❌Urethra: not good

AI 🤖better than 👨🏻‍⚕️ 

👏🏻@UCSanDiego MS4 Lily Nguyen

#ASTRO25 #ProstateCancer #radonc
TylerSbrt's tweet image. PURE-MRI study results

How well do physicians contour prostate and urethra on MRI?

✅Prostate, including inexperienced docs

❌Urethra: not good

AI 🤖better than 👨🏻‍⚕️ 

👏🏻@UCSanDiego MS4 Lily Nguyen

#ASTRO25 #ProstateCancer #radonc

If there’s not enough evidence for #ProstateCancer screening, we’ll be disappointed - but we won’t lose hope. Our TRANSFORM trial will deliver the definitive evidence we need. We’re committed to better diagnosis and treatment until no man’s diagnosis is left to chance.

ProstateUK's tweet image. If there’s not enough evidence for #ProstateCancer screening, we’ll be disappointed - but we won’t lose hope.

Our TRANSFORM trial will deliver the definitive evidence we need.

We’re committed to better diagnosis and treatment until no man’s diagnosis is left to chance.

One man dies every 45 minutes from #ProstateCancer - that's half a football match. 👏 That's why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited. 👊 It’s about time we relegated prostate cancer. #BHAFC l @ProstateUnited l @LMA_Managers

ProstateUK's tweet image. One man dies every 45 minutes from #ProstateCancer - that&apos;s half a football match.

👏 That&apos;s why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited.

👊 It’s about time we relegated prostate cancer.

#BHAFC l @ProstateUnited l @LMA_Managers
ProstateUK's tweet image. One man dies every 45 minutes from #ProstateCancer - that&apos;s half a football match.

👏 That&apos;s why @OfficialBHAFC gaffer Fabian Hürzeler and his players are standing with #ProstateUnited.

👊 It’s about time we relegated prostate cancer.

#BHAFC l @ProstateUnited l @LMA_Managers

@Reddy4Urology presenting results of a multicentre evaluation of infield recurrence after #HIFU or #cryotherapy for #prostatecancer at therapy_focal in Washington, USA.

LabBryant's tweet image. @Reddy4Urology presenting results of a multicentre evaluation of infield recurrence after #HIFU or #cryotherapy for #prostatecancer at therapy_focal in Washington, USA.
LabBryant's tweet image. @Reddy4Urology presenting results of a multicentre evaluation of infield recurrence after #HIFU or #cryotherapy for #prostatecancer at therapy_focal in Washington, USA.

Prostate cancer w/foamy gland features - note the pyknotic nuclei in foamy glands = deceptively benign-appearing Fortunately, as in this example, often admixed with usual acinar #prostatecancer with more amphophilic cytoplasm, prominent nucleoli, etc. #gupath

rovingatuscap's tweet image. Prostate cancer w/foamy gland features - note the pyknotic nuclei in foamy glands = deceptively benign-appearing

Fortunately, as in this example, often admixed with usual acinar #prostatecancer with more amphophilic cytoplasm, prominent nucleoli, etc. #gupath

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile…

_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…
_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…
_ShankarSiva's tweet image. 🚫 In &amp;gt;2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile…

45 years ago today we got married. 8 years ago I was told I only had 2 years to live thanks to stage 4 #prostatecancer and I didn’t think we’d get to 40 years let alone 45! Now I’m optimistic we’ll get to 50! Don’t think we’ve changed a bit in 45 years 😂😂😂

ethansgrumps's tweet image. 45 years ago today we got married.

8 years ago I was told I only had 2 years to live thanks to stage 4 #prostatecancer and I didn’t think we’d get to 40 years let alone 45! Now I’m optimistic we’ll get to 50! 

Don’t think we’ve changed a bit in 45 years 😂😂😂
ethansgrumps's tweet image. 45 years ago today we got married.

8 years ago I was told I only had 2 years to live thanks to stage 4 #prostatecancer and I didn’t think we’d get to 40 years let alone 45! Now I’m optimistic we’ll get to 50! 

Don’t think we’ve changed a bit in 45 years 😂😂😂

Beautiful work @LambAlastair mapping the clonal evolution of #prostatecancer through both biopsy and RP tissue. #addmetech25

dr_coops's tweet image. Beautiful work @LambAlastair mapping the clonal evolution of #prostatecancer through both biopsy and RP tissue. #addmetech25

Men with PSA <1–2 ng/ml at 60 are very unlikely to die from prostate cancer. Screening them again may just cause harm, not help. #ProstateCancer @JNCI_Now @APCCC_Lugano @PCFnews doi.org/10.1093/jnci/d…

DrYukselUrun's tweet image. Men with PSA &amp;lt;1–2 ng/ml at 60 are very unlikely to die from prostate cancer. Screening them again may just cause harm, not help. 
#ProstateCancer 
@JNCI_Now @APCCC_Lugano @PCFnews 
doi.org/10.1093/jnci/d…

🆕 in European Urology (Editor’s Choice) Systematic review of MRI in prostate cancer screening: ✔ Improves detection of clinically significant PCa ✔ Cuts unnecessary biopsies ✔ Best results with 2nd-stage MRI after PSA Full text 👉buff.ly/wILefD8 #ProstateCancer #MRI

EUplatinum's tweet image. 🆕 in European Urology (Editor’s Choice)
Systematic review of MRI in prostate cancer screening:
✔ Improves detection of clinically significant PCa
✔ Cuts unnecessary biopsies
✔ Best results with 2nd-stage MRI after PSA
Full text 👉buff.ly/wILefD8 
#ProstateCancer #MRI…

#ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer @myESMO

dmukherji's tweet image. #ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer @myESMO

A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere. #prostatecancer @therapy_focal

CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal
CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal
CMillaVanilla2's tweet image. A huge thank you to Dr. Srinivas Vourganti for sharing his insight and experience at #FOCAL2025! 

It’s leaders like @vourganti, dedicated to advancing care through innovation, that continue to shape better outcomes for patients everywhere.

#prostatecancer @therapy_focal

Loading...

Something went wrong.


Something went wrong.


United States Trends